The AMR Crisis: A Ticking Time Bomb for Minimally Invasive Surgeries

In modern medicine, minimally invasive surgeries (MIS) stand as a testament to the
advancements in surgical techniques and technology. These procedures, characterised by
smaller incisions, reduced pain, quicker recovery times, and lower risk of complications
than traditional open surgeries, have revolutionised patient care. However, the very
foundation of MIS is now under threat from a growing and insidious crisis: antibiotic
resistance. This looming threat is akin to a ticking time bomb, poised to undermine the
safety and efficacy of surgical interventions and patient outcomes.

Understanding Antibiotic Resistance

Antibiotic resistance occurs when bacteria evolve mechanisms that protect them from the
effects of antibiotics. This resistance can develop through several pathways, including
genetic mutations and the acquisition of resistance genes from other bacteria. Factors
contributing to the acceleration of antibiotic resistance include:

1. Overuse and Misuse of Antibiotics: In both healthcare and agriculture, antibiotics
   are frequently used indiscriminately, often for conditions that do not require them,
   such as viral infections.
2. Incomplete Treatment Courses: Patients sometimes fail to complete prescribed
   antibiotic courses, which can allow partially resistant bacteria to survive and
   proliferate.
3. Inadequate Infection Control: Poor infection control practices in healthcare
   settings can facilitate the spread of resistant bacteria.
4. Global Travel and Trade: Increased global movement of people and goods can
   spread resistant bacteria across borders, exacerbating the problem on a global
   scale.

The Crucial Role of Prophylactic Antibiotics in Surgery

In the context of MIS, prophylactic antibiotics are a critical component of patient care.
These antibiotics are administered before, during, and sometimes after surgery to prevent
post-operative infections. Despite the minimally invasive nature of these procedures, the
risk of bacterial contamination and subsequent infection remains significant due to the
introduction of surgical instruments into sterile body cavities.

The Impending Crisis for Minimally Invasive Surgeries

The rise of antibiotic-resistant bacteria poses a severe threat to the efficacy of
prophylactic antibiotics. As bacteria develop resistance to the commonly used antibiotics,
the risk of post-operative infections increases dramatically. These infections can be
severe, difficult to treat, and in some cases, life-threatening.

Implications for Patient Safety and Surgical Outcomes

The impact of antibiotic resistance on MIS is multifaceted and far-reaching:

1. Increased Infection Rates: With resistant bacteria rendering standard prophylactic
   antibiotics ineffective, patients undergoing MIS are at a higher risk of developing
   infections. These infections can lead to complications, extended hospital stays, and
   additional surgical interventions.
2. Higher Healthcare Costs: Treating antibiotic-resistant infections is significantly
   more expensive than treating infections with standard antibiotics. The increased
   use of more potent, expensive antibiotics, prolonged hospitalisations, and the need
   for additional treatments contribute to escalating healthcare costs.
3. Compromised Surgical Outcomes: The benefits of MIS, such as reduced recovery
   times and lower complication rates, may be compromised by the increased
   incidence of infections. This could negate the advantages of MIS over traditional
   open surgeries.
4. Increased Morbidity and Mortality: In severe cases, antibiotic-resistant infections
   can lead to higher morbidity and mortality rates. The inability to effectively treat
   these infections can result in devastating outcomes for patients.

The Urgent Need for Solutions

Addressing the antibiotic resistance crisis requires a comprehensive, multifaceted
approach:

1. Antibiotic Stewardship Programs: Implementing robust antibiotic stewardship
   programs is essential. These programs promote the appropriate use of antibiotics,
   ensuring they are prescribed only when necessary and in the correct dosages.
   Stewardship programs can help reduce the overuse and misuse of antibiotics,
   thereby slowing the development of resistance.
2. Enhanced Infection Control Practices: Healthcare facilities must prioritise
   stringent infection control measures. This includes regular hand hygiene, proper
   sterilisation of surgical instruments, and isolation protocols for patients with
   resistant infections. Effective infection control can prevent the spread of resistant
   bacteria within healthcare settings.
3. Research and Development: Investing in the research and development of new
   antibiotics and alternative therapies is crucial. Pharmaceutical companies and
   research institutions must prioritise the discovery of novel antibiotics that can
   overcome resistant bacteria. Additionally, exploring non-antibiotic treatments,
   such as bacteriophage therapy and immunotherapy, offers promising avenues for
   combating resistant infections.
4. Global Surveillance and Collaboration: A coordinated global effort is needed to
   monitor and combat antibiotic resistance. International collaboration can facilitate
   the sharing of data, best practices, and resources. Organisations such as the World
   Health Organisation (WHO) play a vital role in coordinating these efforts.
5. Public Education and Awareness: Educating the public about the responsible use
   of antibiotics is critical. Patients need to understand the importance of completing
   prescribed antibiotic courses and the dangers of self-medicating with leftover
   antibiotics. Public awareness campaigns can help change behaviours and reduce
   the misuse of antibiotics.
6. Policy and Regulation: Governments must implement and enforce policies that
   regulate the use of antibiotics in both healthcare and agriculture. Policies that
   restrict the over-the-counter sale of antibiotics and promote their judicious use can
   help curb the rise of resistance.

Conclusion: A Call to Action

The antibiotic resistance crisis represents a ticking time bomb that threatens to dismantle
the advancements made in minimally invasive surgery and surgical medicine as a whole.
It calls for urgent, coordinated action from healthcare professionals, researchers,
policymakers, and the public. By adopting comprehensive strategies to combat antibiotic
resistance, we can preserve the efficacy of prophylactic antibiotics, safeguard patient
safety, and ensure that minimally invasive surgeries continue to offer their significant
benefits.
The time to act is now, before this crisis escalates beyond control, compromising the very
foundations of modern medical practice and endangering countless lives. The future of
minimally invasive surgery and patient care depends on our ability to defuse this ticking
time bomb of antibiotic resistance.

References

1. Centres for Disease Control and Prevention (CDC):
   ○ Centres for Disease Control and Prevention. (2021). Antibiotic Resistance
   Threats in the United States.
2. World Health Organisation (WHO):
   ○ World Health Organisation. (2020). Global Action Plan on Antimicrobial
   Resistance.
3. The Lancet Infectious Diseases:
   ○ The Lancet Infectious Diseases. (2019). Antimicrobial Resistance: The
   Silent Threat.
4. National Institute of Allergy and Infectious Diseases (NIAID):
   ○ National Institute of Allergy and Infectious Diseases. (2021). Antibiotic
   Resistance.
5. MayoClinic:
   ○ MayoClinic. (2022). Antibiotic Stewardship.
6. National Institutes of Health (NIH):
   ○ National Institutes of Health. (2021). The Problem of Antibiotic Resistance.
7. European Centre for Disease Prevention and Control (ECDC):
   ○ European Centre for Disease Prevention and Control. (2020). Antimicrobial
   Resistance Surveillance in Europe.
8. Journal of the American Medical Association (JAMA):
   ○ Kourtis, A. P., Hatfield, K., Baggs, J., Mu, Y., See, I., Epson, E., … &
   Reddy, S. C. (2019). Vital signs: epidemiology and recent trends in
   methicillin-resistant and in methicillin-susceptible Staphylococcus aureus
   bloodstream infections—United States. JAMA, 321(8), 758-768.
9. NewEngland Journal of Medicine (NEJM):
   ○ Theuretzbacher, U., Outterson, K., Engel, A., & Karlén, A. (2020). The
   global preclinical antibacterial pipeline. NEJM, 383(6), 586-587.
   10.World Economic Forum:
   ○ World Economic Forum. (2021). Why We Need to Take Action on
   Antibiotic Resistance.